Acurx price target lowered to $12 from $14 at H.C. Wainwright

H.C. Wainwright analyst Ed Arce lowered the firm’s price target on Acurx Pharmaceuticals to $12 from $14 and keeps a Buy rating on the shares following the Q4 report. The company announced plans to initiate the first of two registrational Phase 3 trials of ibezapolstat as a treatment for patients with clostridioides difficile infection in Q4, with a goal to complete in a year and a half, or in Q2 of 2026, the analyst tells investors in a research note.